Phase
Startup
RECCAN
Early detection of pancreatic cancer.
For most pancreatic cancer patients, the diagnosis comes too late, when the disease is no longer curable. Earlier diagnosis takes 5-year survival expectancy from a couple of percent to more than 40%, but efficient means of screening is lacking.
With a diagnostic test for the early diagnosis of pancreatic cancer, Reccan addresses the global market for both monitoring high-risk patients and early detection when symptoms arise. The Reccan Immunoassay, along with its accompanying software, is built on biomarkers specific to pancreatic cancer.
Reccan is based on extensive research by Professor Roland Andersson, MD, at Lund University and decades of surgical experience. Malin Bornschein, PhD and the CEO of Reccan, comes with broad experience from several positions within the life sciences industry.
Did you know?
Our founder Professor Roland Andersson has been active within pancreatic cancer surgery for almost 40 years!
Medicines for acute systemic inflammatory diseases
Cancer immunotherapies based in cell reprogramming
Cell factories for dairy processing
Automated microscopy image acquisition and analysis
Implants of magnesium alloys
Developing future targeted immunotherapies in cancer
Digital service for patients
Medical device that reduces pain during vein operation
Cloud-based solutions for genomics data
A reusable, user-friendly, and sustainable pregnancy test
Digital assistive device for post-surgical rehabilitation
Develops the first effective treatment for hypothyroidism
Builds gene therapy viral vectors
Early detection of pancreatic cancer
Bio-based vegan coating for fruits and vegetables
Equipment that improves the function of cultivated cells
Medtech solution for preventing pressure ulcers
Effective treatments for brain tumors
A new suturing choice for abdominal wall closure
Converting waste flows into valuable raw materials
Innovative systemic anti-inflammatory treatments
Safer medical needles for prostate biopsy
